Pediatria Polska
en ENGLISH
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
1/2026
vol. 101
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Opis przypadku

The case of a patient with familial cold autoinflammatory syndrome-2 caused by the NLRP12 mutation associated with severe polyarthritis

Magdalena Rutkowska-Zapała
1, 2
,
Anna Szaflarska
1, 2

  1. Department of Clinical Immunology, Institute of Pediatrics, Jagiellonian University Medical College, Cracow, Poland
  2. Department of Clinical Immunology, Children’s University Hospital, Cracow, Poland
Pediatr Pol 2026; 101 (1): 81-86
Data publikacji online: 2026/03/16
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Familial cold autoinflammatory syndrome-2 (FCAS2) is a rare autosomal dominant disorder caused by pathogenic variants in the NLRP12 gene. It is characterized by recurrent non-pruritic urticaria, arthritis, fever, and elevated inflammatory markers, often triggered by cold exposure. Here, we describe a Polish patient with FCAS2 linked to the NLRP12 c.1054C>T (p.Arg352Cys) variant, who developed severe polyarthritis mimicking juvenile idiopathic arthritis (JIA), yet without fever. Urticarial rashes began at 8 months of age and were initially unrelated to cold, but later became cold-induced. Standard therapies with antihistaminic drugs for urticaria and methotrexate for JIA were ineffective. Due to persistent arthritis and high inflammatory markers, anti-IL-1 therapy (anakinra) was initiated, leading to marked clinical and laboratory improvement, confirming the autoinflammatory mechanism. This case broadens the knowledge of NLRP12-related syndromes and underlines the value of genetic testing in atypical arthritis unresponsive to standard treatment.
 
© 2026 Termedia Sp. z o.o.
Developed by Termedia.